Abstract P158 – Table 1. Difference in change from baseline in metabolic, liver and quality of life parameters for the maraviroc + OBT versus OBT group with bootstrapped 95% confidence intervals.
Measure	Week	Number of participants	Difference between groups in change from baseline	95% confidence interval
BMI, kg/m2	48	45	‐0.2	‐1.0 to 0.6
	96	45	‐0.2	‐0.8 to 0.4
Waist circumference, cm	48	43	2.7	‐5.1 to 11
	96	42	1.3	‐7.3 to 9.9
CD4 cell count, cells/mm3	48	45	70	‐35 to 175
	96	44	‐47	‐135 to 41
Fasting glucose, mmol/L	48	44	‐0.1	‐0.8 to 0.7
	96	42	0.8	‐0.4 to 2.1
HbA1c, mmol/mol	48	45	‐2.3	‐6.6 to 2.1
	96	45	2.5	‐3.0 to 8.0
AST, U/L	48	43	‐0.5	‐7.2 to 6.1
	96	38	7.0	‐3.4 to 17
ALT, U/L	48	44	‐5.7	‐22 to 10
	96	45	0.5	‐19 to 20
Fasting triglycerides, mmol/L	48	44	0.7	‐0.1 to 1.4
	96	46	‐0.2	‐1.0 to 0.6
Fasting LDL, mmol/L	48	40	0	‐0.5 to 0.4
	96	41	0	‐0.4 to 0.5
Fasting HDL, mmol/L	48	44	0	‐0.2 to 0.2
	96	46	0.1	‐0.1 to 0.3
Fasting HDL: total cholesterol ratio	48	44	0.3	‐0.6 to 1.1
	96	46	‐0.3	‐1.0 to 0.4
Fasting total cholesterol, mmol/L	48	44	0.1	‐0.4 to 0.6
	96	46	0.1	‐0.4 to 0.7
Fibroscan median liver stiffness, kPa	48	43	‐1.7	‐3.8 to 0.4
	96	41	‐0.2	‐2.0 to 1.6
Fibroscan CAP score, dB/m	48	41	‐15	‐56 to 25
	96	39	‐5.8	‐41 to 30
ELF score	48	43	0.3	0 to 0.6
	96	42	0.1	‐0.3 to 0.4
Chronic Liver Disease Questionnaire for NAFLD	48	45	‐0.3	‐1.0 to 0.4
	96	44	‐0.5	‐1.3 to 0.2